• 1
    de Boer-Dennert M, de Wit R, Schmitz PIM, et al. Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists. Br J Cancer. 1997; 76: 10551061.
  • 2
    Small BE, Holdsworth MT, Raisch DW, Winter SS. Survey ranking of emetogenic control in children receiving chemotherapy. J Pediatr Hematol Oncol. 2000; 22: 125132.
  • 3
    Holdsworth MT, Adams VR, Raisch DW, Wood JG, Winter SS. Computerized system for outcomes-based antiemetic therapy in children. Ann Pharmacother. 2000; 34: 11011108.
  • 4
    Italian Group for Antiemetic Research. Cisplatin-induced delayed emesis: pattern and prognostic factors during three subsequent cycles. Ann Oncol. 1994; 5: 585589.
  • 5
    Kris MG, Pisters KMW, Hinkley L. Delayed emesis following anticancer chemotherapy. Support Care Cancer. 1994; 2: 297300.
  • 6
    Ossi M, Anderson E, Freeman A. 5-HT3 receptor antagonists in the control of cisplatin-induced delayed emesis. Oncology. 1996; 53(Suppl 1): 7885.
  • 7
    Latreille J, Pater J, Johnston D, et al. Use of dexamethasone and granisetron in the control of delayed emesis for patients who receive highly emetogenic chemotherapy. J Clin Oncol. 1998; 16: 11741178.
  • 8
    Italian Group for Antiemetic Research. Prevention of cisplatin-induced delayed emesis: still unsatisfactory. Support Care Cancer. 1999; 8: 229232.
  • 9
    Roila F, Donati D, Tamberi S, Margutti G. Delayed emesis: incidence, pattern, prognostic factors and optimal treatment. Support Care Cancer. 2002; 10: 8895.
  • 10
    Dupuis LL, Lau R, Greenberg ML. Delayed nausea and vomiting in children receiving antineoplastics. Med Pediatr Oncol. 2001; 37: 115121.
  • 11
    Holdsworth MT, Raisch DW, Duncan MH, Chavez CM, Leasure MM. Assessment of chemotherapy-induced emesis and evaluation of a reduced-dose intravenous ondansetron regimen in pediatric outpatients with leukemia. Ann Pharmacother. l995; 29: l62l.
  • 12
    ASHP Commission on Therapeutics. ASHP therapeutic guidelines on the pharmacologic management of nausea and vomiting in adult and pediatric patients receiving chemotherapy or radiation therapy or undergoing surgery. Am J Health Syst Pharm. 1999; 56: 729764.
  • 13
    Gralla RJ, Osoba D, Kris MG, et al. Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. J Clin Oncol. 1999; 17: 29712994.
  • 14
    Multinational Association for Supportive Care in Cancer. Antiemetic guidelines. March, 2004. Available at URL: [accessed May 15, 2005].
  • 15
    Linet MS, Ries LAG, Smith MA, Tarone RE, Devesa SS. Cancer surveillance series: recent trends in childhood cancer incidence and mortality in the United States. J Natl Cancer Inst. 1999; 91: 10511058.
  • 16
    Hickok JT, Roscoe JA, Morrow GR, King DK, Atkins JN, Fitch TR. Nausea and emesis remain significant problems of chemotherapy despite prophylaxis with 5-hydroxytryptamine-3 antiemetics. Cancer. 2003; 97: 28806.
  • 17
    Grunberg SM, Deuson RR, Mavros P, et al. Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Perception versus reality. Cancer. 2004; 100: 22612268.
  • 18
    Watamura SE, Donzella B, Kertes DA, Gunnar MR. Developmental changes in baseline cortisol activity in early childhood: relations with napping and effortful control. Dev Psychobiol. 2004; 45: 125133.
  • 19
    Fredrikson M, Hursti T, Furst CJ, et al. Nausea in cancer chemotherapy is inversely related to urinary cortisol excretion. Br J Cancer. 1992; 65: 779780.
  • 20
    Zeltzer LK, LeBaron S, Zeltzer PM. A prospective assessment of chemotherapy-related nausea and vomiting in children with cancer. Am J Pediatr Hematol Oncol. 1984; 6: 516.
  • 21
    Zeltzer L, LeBaron S, Zeltzer PM. Paradoxical effects of prophylactic phenothiazine anti-emetics in children receiving chemotherapy. J Clin Oncol. 1984; 2: 930936.